Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 2

Sponsor Class

INDUSTRY 352OTHER 60OTHER_GOV 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Mesothelioma, Malignant 6Solid Tumor 4Mesothelioma 3Solid Tumors 2Pediatric Solid Tumors 2Advanced Solid Tumor 2Thymoma 1Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Solid Tumor, Adult 1Retinoblastoma 1Refractory Solid Tumors 1Pleural Effusion, Malignant 1Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Malignant Solid Tumor 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Heart Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Childhood Solid Tumor 1Carcinoma, Hepatocellular 1

Interventions

spartalizumab 1pembrolizumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Advanced Solid Tumor × Other solid neoplasm × Clear all
NCT04268108 2020-06-11

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

Henan Cancer Hospital

Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡